Repertoire Immune Medicines
PrivateLast Round
Series B
Apr 13, 2021
Total Funding Raised
$214M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Repertoire Immune Medicines is a biotechnology company that develops targeted therapies for cancer, autoimmune disorders, and infectious diseases using its proprietary DECODE platform to map T cell receptor-antigen interactions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Repertoire Immune Medicines Comparables
Compare Repertoire Immune Medicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Enara Bio | 82% | |
| TScan Therapeutics | 77% | |
| BlueSphere Bio | 76% | |
Repertoire Immune Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 13, 2021 | ||||
| Grant | Jun 24, 2020 | ||||
| Early Funding | Mar 12, 2020 | ||||
| Series A | Nov 14, 2017 |
Repertoire Immune Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SoftBank Investment Advisers | Series B |
| Public Sector Pension Investment Board | Series B |
| Covid19 HPC Consortium | Grant |
| SoftBank Group | Series B |
| Invus Opportunities | Series B |
| JDRF | Early Funding |
| Flagship Pioneering | Series B, Series A, Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 31% MoM, reaching 6.1K.
- Apr 1, 2026
Announced strategic collaboration with Pfizer.
Repertoire Immune Medicines Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Repertoire Immune Medicines's valuation, stock price, and market status.